745 related articles for article (PubMed ID: 16937391)
1. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
2. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
3. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.
Uberti JP; Ayash L; Ratanatharathorn V; Silver S; Reynolds C; Becker M; Reddy P; Cooke KR; Yanik G; Whitfield J; Jones D; Hutchinson R; Braun T; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2005 Sep; 11(9):680-7. PubMed ID: 16125638
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
5. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
6. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
[TBL] [Abstract][Full Text] [Related]
8. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
9. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Akpek G; Lee SM; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
[TBL] [Abstract][Full Text] [Related]
10. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
13. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
16. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory chronic GVHD with rituximab: a GITMO study.
Zaja F; Bacigalupo A; Patriarca F; Stanzani M; Van Lint MT; Filì C; Scimè R; Milone G; Falda M; Vener C; Laszlo D; Alessandrino PE; Narni F; Sica S; Olivieri A; Sperotto A; Bosi A; Bonifazi F; Fanin R;
Bone Marrow Transplant; 2007 Aug; 40(3):273-7. PubMed ID: 17549053
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
[TBL] [Abstract][Full Text] [Related]
20. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
